436 Studies Now Enrolling
Phase 1 Study of IMC-CS4, a Monoclonal Antibody Targeted to the CSF-1 Receptor (CSF-1R), in Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available
A study for patients with advanced solid tumors using study drug IMC-CS4
| Sponsor: | Eli Lilly and Company |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAQ8124 |
| U.S. Govt. ID: | NCT01346358 |
| Contact: | Richard Carvajal: 646-317-6041 / carvajalr@columbia.edu |
Additional Study Information:
The purpose of this study is to see if IMC-CS4 (LY3022855) is safe to give to patients. We want to see how you feel when you are receiving treatment, what effects, good and/or bad, the study drug has on you and your tumor and which may be the best dose.
This study is closed
